Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Gains from Investment Securities (2019 - 2021)

Benitec Biopharma's Gains from Investment Securities history spans 3 years, with the latest figure at $794000.0 for Q3 2021.

  • For Q3 2021, Gains from Investment Securities changed N/A year-over-year to $794000.0; the TTM value through Jun 2022 reached $794000.0, changed N/A, while the annual FY2022 figure was $794000.0, N/A changed from the prior year.
  • Gains from Investment Securities for Q3 2021 was $794000.0 at Benitec Biopharma, up from -$580000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $794000.0 in Q3 2021 and bottomed at -$580000.0 in Q2 2020.
  • The 3-year median for Gains from Investment Securities is $579000.0 (2019), against an average of $264333.3.